Skip to main content

Table 1 Radiological stages, lung function tests parameters, frequency of patients with Löfgren syndrome, abnormal laboratory results, % of patients on treatment and disease duration in patients at initial evaluation (V1) and follow-up (V2) visits.

From: Exhaled 8-isoprostane as a prognostic marker in sarcoidosis. A short term follow-up

Feature

Visit 1

Visit 2

Stage I

23 (57.5%)

13 (-10 with CR)

Stage II

9 (22.5%)

8 (-1 with CR)

Stage III

8 (20%)

8 (no CR)

FEV1 (% predicted)

92.6 ± 3.2

93.8 ± 3.1

FVC (% predicted)

97.9 ± 3.0

99.7 ± 2.9

FEV1/FVC (%)

0.81 ± 0.02

0.80 ± 0.02

DLCOc (% predicted)

87.3 ± 3.4

87.7 ± 3.7

LS present and past

20 (50%)

-

LS present

15 (37.5%)

0

SACE > 68 IU/L

11 (27.5%)

5 (12.5%)

S-Ca2+ > 2.62 mmol/L

1 (2.5%)

2 (5%)

U-Ca2+ > 7.5 mmol/24 h

3 (7.5%)

5 (12.5%)

CRP > 5 mg/L

15 (37.5%)

5 (12.5%)

On treatment

0

8 (20%)

T from first symptoms to V1

(weeks, median: 25-75 percentile)

10 [4-60]

-

  1. CR – complete remission, DLCOc – diffusion capacity for CO corrected for hemoglobin, FEV1 #8211; forced expiratory volume in 1st second of expiration, FVC – forced vital capacity, LS – Löfgren syndrome, S – serum, SACE – serum angiotensin converting enzyme, T – time, U – urine.